This article is more than 5 years old. Information may no longer be current.

Wound-healing compound may be effective for ocular indications

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BETHESDA, Md. – Thymosin beta 4, or TB4, may have wound-healing effects in the eye, according to RegeneRx, the compound’s developer.

The company announced that three studies concerning TB4’s potential ophthalmic applications will be presented at the Association for Research in Vision and Ophthalmology meeting next month.

In one study, TB4 was found to stimulate MMP-1, an enzyme that plays a “key role” in wound healing, RegeneRx said in a press release. In a second study, TB4 was found to exert its anti-inflammatory properties by down-regulating another enzyme and decreasing IL-8 expression. IL-8 is a protein expressed by injured and stressed cells that trigger the migration of white blood cells to the site of an injury, the release said. A third study indicates that TB4 is “essential for its anti-apoptotic effect on human cornea epithelial cells” that were exposed to toxins, the company said.